Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 2,646.6	$ 2,261.4
Marketable securities	2,151.3	1,541.1
Accounts receivable, net	1,567.6	1,549.4
Due from anti-CD20 therapeutic programs	435.9	412.3
Inventory	1,294.2	1,351.5
Other current assets	1,645.3	740.8
Total current assets	9,740.9	7,856.5
Marketable securities	1,102.9	892.0
Property, plant and equipment, net	3,355.1	3,416.4
Operating lease assets	321.1	375.4
Intangible assets, net	2,075.3	2,221.3
Goodwill	5,749.6	5,761.1
Deferred tax asset	1,235.7	1,415.1
Investments and other assets	1,500.8	1,939.5
Total assets	25,081.4	23,877.3
Current liabilities:
Current portion of notes payable	999.8	999.1
Taxes payable	284.9	174.7
Accounts payable	434.8	589.2
Accrued expense and other	3,298.5	2,535.2
Total current liabilities	5,018.0	4,298.2
Notes payable	6,277.4	6,274.0
Deferred tax liability	480.6	694.5
Long-term operating lease liabilities	274.2	330.4
Other long-term liabilities	1,167.8	1,320.5
Total liabilities	13,218.0	12,917.6
Commitments, contingencies and guarantees
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	68.2
Accumulated other comprehensive income (loss)	(110.4)	(106.7)
Retained earnings	14,959.9	13,911.7
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	11,872.5	10,896.2
Noncontrolling interests	(9.1)	63.5
Total equity	11,863.4	10,959.7
Total liabilities and equity	$ 25,081.4	$ 23,877.3